Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity

E-ISSN： 1549-490x|23|1|1-1

ISSN： 1083-7159

Source： The Oncologist, Vol.23, Iss.1, 2018-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GNOSIS: Guidelines for Neuro-Oncology: Standards for Investigational Studies — reporting of surgically based therapeutic clinical trials

By Chang Susan Vogelbaum Michael Lang Frederick Haines Stephen Kunwar Sandeep Chiocca E. Olivi Alessandro Quinones-Hinojosa Alfredo Parsa Andrew Warnick Ronald

Journal of Neuro-Oncology, Vol. 82, Iss. 2, 2007-04 ,pp. : 211-220

Springer Publishing Company

Access to resources Recommend Favorite

A Systematic Review of Health‐Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 203-213

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cancer Cachexia: It’s Time for More Clinical Trials

By Bossola Maurizio Pacelli Fabio Tortorelli Antonio Doglietto Giovan

Annals of Surgical Oncology, Vol. 14, Iss. 2, 2007-02 ,pp. : 276-285

Springer Publishing Company

Access to resources Recommend Favorite

HIPEC: The Complexities of Clinical Trials

By Bartlett David

Annals of Surgical Oncology, Vol. 15, Iss. 5, 2008-05 ,pp. : 1277-1279

Springer Publishing Company

Access to resources Recommend Favorite

Clinical trials of targeted toxins

By Frankel A.E. Tagge E.P. Willingham M.C.

Seminars in Cancer Biology, Vol. 6, Iss. 5, 1995-10 ,pp. : 307-317

Academic Press

Access to resources Recommend Favorite